PT - JOURNAL ARTICLE AU - Hoertel, Nicolas AU - Rico, Marina Sanchez AU - Vernet, Raphaël AU - Jannot, Anne-Sophie AU - Neuraz, Antoine AU - Blanco, Carlos AU - Lemogne, Cédric AU - Airagnes, Guillaume AU - Paris, Nicolas AU - Daniel, Christel AU - Gramfort, Alexandre AU - Lemaitre, Guillaume AU - Bernaux, Mélodie AU - Bellamine, Ali AU - Beeker, Nathanaël AU - Limosin, Frédéric AU - , TI - Observational Study of Chlorpromazine in Hospitalized Patients with Covid-19 AID - 10.1101/2020.07.15.20154310 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.15.20154310 4099 - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154310.short 4100 - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154310.full AB - On the grounds of its anti-inflammatory and potential antiviral effects, chlorpromazine has been suggested to be effective treatment for Covid-19. We examined the association between chlorpromazine use and respiratory failure among all hospitalized adults with Covid-19 at the 39 Greater Paris University hospitals since the beginning of the epidemic. Study baseline was defined as the date of hospital admission. The primary endpoint was a composite of intubation or death in a time-to-event analysis adjusting for numerous potential confounders. We used a multivariable Cox model with inverse probability weighting according to the propensity score. Of the 12,217 adult inpatients with a positive Covid-19 RT-PCR test included in the analyses, 57 (0.47%) received chlorpromazine. Over a mean follow-up of 20.8 days, the primary endpoint occurred in 29 patients (50.9%) exposed to chlorpromazine and 1,899 patients (15.6%) who were not. In the main analysis, there was a positive significant association between chlorpromazine use and the outcome (HR, 1.67; 95% CI, 1.09 to 2.56, p=0.019), while a Cox regression in a matched analytic sample yielded non-significant association (1.38; 95% CI, 0.91 to 2.09, p=0.123). These findings suggest that chlorpromazine is unlikely to have a clinical efficacy for Covid-19.Competing Interest StatementDr Hoertel has received personal fees and non-financial support from Lundbeck, outside the submitted work. Dr Lemogne reports personal fees and non-financial support from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical, and Boehringer Ingelheim, outside the submitted work. Dr Airagnes reports personal fees from Pfizer, Pierre Fabre and Lundbeck, outside the submitted work. Dr Limosin has received speaker and consulting fees from Janssen-Cilag outside the submitted work. Other authors declare no competing interests.Funding StatementThis work did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This observational non-interventional retrospective study using routinely collected data received approval from the Institutional Review Board of the AP-HP clinical data warehouse (decision CSE-20-20_COVID19, IRB00011591). AP-HP clinical Data Warehouse initiative ensures patients' information and consent regarding the different approved studies through a transparency portal in accordance with European Regulation on data protection and authorization number 1980120 from National Commission for Information Technology and Civil Liberties (CNIL).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the AP-HP Health Data Warehouse can be obtained at https://eds.aphp.fr//.